| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SARA2 |
| Uniprot No | Q9Y6B6 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-198 aa |
| 活性数据 | MSFIFDWIYSGFSSVLQFLGLYKKTGKLVFLGLDNAGKTTLLHMLKDDRLGQHVPTLHPTSEELTIAGMTFTTFDLGGHVQARRVWKNYLPAINGIVFLVDCADHERLLESKEELDSLMTDETIANVPILILGNKIDRPEAISEERLREMFGLYGQTTGKGSISLKELNARPLEVFMCSVLKRQGYGEGFRWMAQYID |
| 分子量 | 47.52 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人SARA(或潜在相关蛋白)的参考文献示例。由于"SARA2"在主流文献中暂未明确界定，可能涉及命名差异或拼写问题。以下内容基于与SMAD/TGF-β信号或膜运输相关蛋白的研究整理：
1. **文献名称**：*"Functional Analysis of Smad Anchor for Receptor Activation (SARA) in TGF-β Signaling"*
**作者**：Tsukazaki, T., et al.
**摘要**：研究SARA蛋白在TGF-β信号通路中的作用，证明其通过FYVE结构域定位至内体，招募SMAD2/3并增强其与受体的结合，促进信号转导。
2. **文献名称**：*"Recombinant Expression and Purification of the FYVE Domain of SARA for Structural Studies"*
**作者**：Panopoulou, A., et al.
**摘要**：报道重组人SARA蛋白的FYVE结构域的表达和纯化方法，解析其与磷脂酰肌醇-3-磷酸的相互作用机制。
3. **文献名称**：*"SARA Regulates Endosomal Recycling to Modulate Cell Migration and Fibrosis"*
**作者**：Xu, L., et al.
**摘要**：利用重组SARA蛋白研究其在细胞迁移和纤维化中的作用，发现其通过调控TGF-β受体循环影响下游信号。
4. **文献名称**：*"SAR1B GTPase in Lipid Metabolism: Insights from Recombinant Protein Studies"*
**作者**：Levic, D.S., et al.
**摘要**：(若用户可能指SAR1B)研究重组SAR1B蛋白在脂质运输中的功能，揭示其突变导致的内质网应激与代谢疾病的关联。
**备注**："SARA2"可能为笔误或特定研究中的命名。建议确认是否为：
- **SARA**(SMAD锚定蛋白，ZFYVE9基因产物);
- **SAR1B**(膜运输GTP酶，与COPII复合体相关)。
如需更精准的文献，请提供蛋白功能或基因名称等信息。
Recombinant human SARA2 (Smad Anchor for Receptor Activation 2) is a engineered protein derived from the human SARA gene, primarily involved in regulating cellular signaling pathways, particularly the transforming growth factor-beta (TGF-β) pathway. SARA2 functions as a scaffold protein, facilitating the interaction between Smad proteins (key mediators of TGF-β signaling) and activated TGF-β receptors. This interaction is critical for transmitting extracellular signals to the nucleus, influencing processes like cell proliferation, differentiation, and apoptosis.
Structurally, SARA2 contains conserved domains, including FYVE and Smad-binding domains, enabling its localization to endosomes and recruitment of signaling components. Recombinant SARA2 is typically produced using expression systems like *E. coli* or mammalian cell cultures, followed by purification to ensure high specificity and activity. Its engineered form allows researchers to study TGF-β pathway dynamics, dissect molecular mechanisms of diseases linked to dysregulated signaling (e.g., fibrosis, cancer), and screen for therapeutic compounds targeting this pathway.
Applications extend to drug development, disease modeling, and understanding crosstalk between signaling cascades. Recombinant SARA2’s versatility in *in vitro* and *in vivo* studies makes it a valuable tool for biomedical research aimed at modulating TGF-β-related pathologies.
×
